IGE AND ANTI IGE THERAPY IN ASTHMA AND ALLERGIC DISEASE (HB 2002). Cet article n’est pas disponible.IGE AND ANTI IGE THERAPY IN ASTHMA AND ALLERGIC DISEASE (HB 2002)

Exploring the role of Immunoglobulin-E (IgE) in human disease, this reference summarizes current research on the mechanisms and utilization of anti-IgE therapeutics in the treatment of IgE-mediated allergic disease, inflammation, and asthma-discussing the structural composition of high- and low-affinity IgE receptors, the airway cells that express these receptors, and the functional activity of IgE-FceRI and IgE-FceRII interactions for improved control and management of allergic disorders.

Compiles previously unpublished data from the first extensive scientific investigations of Xolair!

IgE and Anti-IgE Therapy in Asthma and Allergic Disease

reviews studies on the distribution of serum IgE levels of normal and asthmatic populations in developed regions of the world such as the United States, Canada, Scandinavia, New Zealand, and Europe

offers novel methods for the design and formulation of monoclonal antibodies

discusses the use of allergen bronchoprovocation to identify the characteristics and efficacy of new antiasthma and antiallergy medications

examines the role of IgE in food and parasitic allergies
and covers

the pathogenesis of atopic dermatitis and urticaria

novel strategies to target mast cells and basophils

murine models of allergic pulmonary inflammation

the pathophysiology of allergic rhinitis
Supplemented with nearly 2000 contemporary references to facilitate further study, IgE and Anti-IgE Therapy in Asthma and Allergic Disease is an in-depth and timely source for basic and clinical immunologists; allergists; pulmonologists and pulmonary disease specialists; physiologists; molecular, cellular, and lung biologists; pediatricians; internists; and graduate and medical school students in these disciplines.

Robert Fick